Ixekizumab (4) (Taltz®) – Plaque psoriasis (PP), ≥ 6 to < 18 years, body weight ≥ 25 kg

1. Characteristics

Start date 01.08.2020
Resolution 21.01.2021
INN Ixekizumab
Brand name Taltz®
Company Lilly Deutschland GmbH
G-BA procedure ID 2020-08-01-D-570
ATC code L04AC13
ICD-10 codes L40.0Nummular psoriasis
DDD 2.9 mg P
Therapeutic area Skin diseases
Reason for procedure New indication
Evidence transfer: Ixekizumab (17.08.2017)
Specialties Bundling

Indication (German)

Taltz is indicated for the treatment of moderate to severe plaque psoriasis in children from the age of 6 years and with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy.

Subgroup Indication Comparator
Kinder und Jugendliche ab 6 Jahren mit mittelschwerer bis schwerer chronischer Plaque-Psoriasis und einem Körpergewicht von mindestens 25 kg, die für eine systemische Therapie in Frage kommen Adalimumab oder Etanercept oder Ustekinumab

9. Associated procedures

Resolution INN Brand name Indication Additional benefit
Ixekizumab Taltz® Plaque psoriasis (PP)
Ixekizumab (2) Taltz® Psoriatic arthritis (PA)
Ixekizumab (3) Taltz® Axial spondyloarthritis
Ixekizumab (4) Taltz® Plaque psoriasis (PP), ≥ 6 to < 18 years, body weight ≥ 25 kg


<< List of all resolutions